AS
Ajinkya Sureshchandra Gawande
About Ajinkya Sureshchandra Gawande
Data last updated:
Ajinkya Sureshchandra Gawande is a Director at Medihope Lifesciences Private Limited (since 2022). The company operates in Pharma. Medihope Lifesciences Private Limited reported revenue of ₹78.5 Lakh (FY 2023).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Medihope Lifesciences Private Limited U51909MH2019PTC334901 | Director | 27 Jun 2022 | 2019 | ₹78.5 Lakh (FY 2023) | Active |
Board colleagues of Ajinkya Sureshchandra Gawande
| Name | DIN | Company | Designation |
|---|---|---|---|
| Kailas Sahebrao Badgujar | 08647562 | Medihope Lifesciences Private Limited | Director |
| Minal Suchit Shrishrimal | 08647561 | Medihope Lifesciences Private Limited | Director |
| Sonal Kunal Bhavsar | 09187917 | Medihope Lifesciences Private Limited | Director |
| Suchit Rajkumar Shrishrimal | 08647663 | Medihope Lifesciences Private Limited | Director |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Ajinkya Sureshchandra Gawande
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ajinkya Sureshchandra Gawande
Ajinkya Sureshchandra Gawande currently holds 1 directorship: Medihope Lifesciences Private Limited (Director, since 27 Jun 2022, revenue ₹78.5 Lakh (FY 2023)).
Ajinkya Sureshchandra Gawande was first appointed on 27 Jun 2022 as Director at Medihope Lifesciences Private Limited.
The current boards of Ajinkya Sureshchandra Gawande's companies include Kailas Sahebrao Badgujar (Medihope Lifesciences Private Limited), Minal Suchit Shrishrimal (Medihope Lifesciences Private Limited), Sonal Kunal Bhavsar (Medihope Lifesciences Private Limited), Suchit Rajkumar Shrishrimal (Medihope Lifesciences Private Limited).